Fin Cascade
Get Android appGet iOS app

Prices as of 8 Oct 2026 close · Not investment advice

Strides Pharma Science Limited

NSE: STARPharmaceuticals

Share price

₹1,095.30

-0.48% close of 8 Oct 2026

Market cap ₹10,077 CrP/E 17.4

Business score

How strong the business is, in one number. The parts behind it are in Pro.

61

out of 100 · worked out 8 Oct 2026

Your ratios

The numbers you want to see first. Tap Edit to change them.

Market cap

₹10,077 Cr

P/E ratio

17.4

P/B ratio

3.3

ROCE

18.3%

ROE

20.0%

Dividend yield

0.5%

Price & valuation chart

How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.

Prices as of 8 Oct 2026 close52-week high ₹1,235.1052-week low ₹793.55

Answers

Simple answers to the questions investors ask most, from the company's own numbers.

How fast it has been growing

Sales grew 8.1% over the past year, and 7.1% a year over its longer record. Meanwhile what it keeps of every 100 rupees of sales improved from -1.9% to 18.7% over the last four years.

Whether it grew faster than its sector

It grew 7.1% a year against a sector median of 13.1% — 6.0 percentage points slower.

Room to re-rate, or risk of de-rating

Too little price history yet to compare it with its own past.

Whether growth justifies the valuation

Priced at 0.2 times its growth rate, on earnings growth of 71%.

Profit growthPrice per ₹1 profitPer 1% growth
Strides Pharma Science Limited — this one71%/yr17.4×₹0.25
Sun Pharmaceutical13%/yr33.4×₹2.6
Divi's Laboratories13%/yr83.3×₹6.4
Torrent Pharmaceuticals22%/yr78.7×₹3.6
Zydus Lifesciences32%/yr23.1×₹0.72
Laurus Labs Limited4%/yr98.6×₹24.7

Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

How it compares with its peers

Against companies the exchange files under the same label (Pharmaceuticals), it ranks 45 of 130 on returns, 90 of 127 on growth, 66 of 130 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

What makes it hard to beat — and is that still true?

A narrow advantage: it earns 18.3% on capital, ahead of 65% of companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

Whether its growth pays for itself

Yes — Over the last five years it made ₹1874 crore of cash from the business, spent ₹775 crore on plant and equipment, and returned ₹1582 crore to lenders and shareholders. And the profit is real: of every 100 rupees it reported over 12 years, about 53 arrived as cash. Its cash comes back more slowly than it used to: it went from being paid 28 days before it paid its own suppliers to waiting 38 days for its cash.

Profit reality check

Is the profit real cash? Simple checks on the accounts. Facts only, not advice.

6 of 9 checks clear · 67%

Latest result · Q1 FY27

What the last results showed. Whether management kept its word is in Pro.

Profit up 56% with margins held at 18.2% despite Rs 13 crore of extra freight cost.

Announced 31 Jul 2026 · Consolidated

Revenue

₹1,265 Cr

Revenue vs last year

+13.0%

Revenue vs last quarter

-4.4%

Net profit

₹165 Cr

Profit vs last year

+56.1%

Profit vs last quarter

+28.3%

Net margin

13.1%

EPS

₹17.02

Earnings call transcript · 31 Jul 2026

Checklist before you investPRO

Points for and against, in one list.

Key numbers & peers

The main numbers grouped by topic, and how the company compares with similar ones.

Price

Market cap
₹10,077 Cr
Prev close
₹1,095.30
52w High
₹1,261
52w Low
₹769
Enterprise value
₹11,622 Cr
Beta
0.9
Price CAGR 1y
38.0%
Price CAGR 3y
67.0%
Price CAGR 5y
32.0%
Price CAGR 10y
9.0%

Ratios

Return on assets
8.4%
PEG ratio
0.2
P/E ratio
17.4
P/B ratio
3.3
EV / EBITDA
12.4
Industry P/E
38.0
ROCE
18.3%
ROCE 5y average
7.0%
ROE
20.0%
Debt / Equity
0.6
Interest coverage
4.7
Dividend yield
0.5%
ROE 3y average
57.0%
ROE last year
20.0%

Annual P&L

Annual revenue
₹4,859 Cr
Annual profit
₹575 Cr
Operating margin
19.0%
Net profit margin
11.8%
EBITDA margin
19.0%
Sales growth 3y
9.6%
Sales growth 5y
7.9%
Profit growth 3y
71.0%
Profit growth 5y
20.0%
EPS
₹60.3
Sales growth TTM
8.0%
Profit growth TTM
55.0%
Dividend payout
8.0%

Quarter P&L

Sales latest quarter
₹1,265 Cr
Profit latest quarter
₹165 Cr
YoY quarterly sales growth
13.0%
YoY quarterly profit growth
55.7%
OPM latest quarter
18.1%

Balance Sheet

Book Value
₹338
Face Value
₹10.0
Total debt
₹1,758 Cr
Total cash
₹213 Cr
Borrowings
₹1,758 Cr
Reserves / Equity
32.8

Cash Flow

Operating cash flow
₹703 Cr
Free cash flow
₹291 Cr
FCF yield
1.1%
Net cash flow
₹76 Cr

Shareholding

Promoter holding
27.9%
FII holding
28.4%
DII holding
15.4%
Public holding
28.3%

Peer comparison

CompanyPrice ₹P/EMkt cap ₹ CrDiv yield %Profit qtr ₹ CrProfit var %Sales qtr ₹ CrSales var %ROCE %
Sun Pharma.Inds.1,749.7533.24,19,8240.902,901.26.015,299.910.520.5
Divi's Lab.9,392.6583.72,49,3450.31902.065.53,080.027.822.0
Torrent Pharma.4,620.1578.81,75,7360.81566.05.84,921.054.915.2
Zydus Lifesci.1,117.2522.91,11,4460.09990.2-35.18,017.022.021.1
Laurus Labs2,011.7599.41,08,6970.10362.1125.52,026.329.117.8
Cipla1,296.0029.31,04,7000.98785.6-39.27,119.32.315.5
Dr Reddy's Labs1,176.0030.598,1580.67435.6-68.78,099.8-5.513.0
Strides Pharma1,073.0017.19,8900.45165.50.81,265.413.018.3
Median416.0034.12,1150.0713.529.5164.018.415.0

Competes with: Aurobindo Pharma, Cipla, Divi's Laboratories, Dr Reddy's Laboratories, Laurus Labs Limited, Lupin, Mankind Pharma Limited, Sun Pharmaceutical, Torrent Pharmaceuticals, Zydus Lifesciences

Quarterly results

Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.

Consolidated · to 30 Jun 2026
Line itemJun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales9309991,0061,0441,0541,1671,1541,1901,1201,2211,1951,3231,265
Expenses7968898768748669839439739029909591,0841,037
Material Cost270261430460409415
Change in Inventories-2.366344-68-0.08-86
Purchases of Stock-in-Trade2321214271127166
Employee Cost223226227230247243
Other Expenses251232247266300297
Operating Profit134111129169188184210218218231236240228
OPM %14111316181618181919201818
Other Income3-12960-273,299254-12018104368
Exceptional items (within Other Income)-27-8.37-8.77-3.30-6.4163
Interest76797071737452504746434241
Depreciation60604948474848494950515356
Profit before tax0-15770233,36986114106122153245148200
Tax %3,025-5235511621201314151317
Net Profit-9-14954103,350729086106132208129165
EPS in Rs-0.79-155.401.983657.819.548.911114221417
Diluted EPS in Rs8.921114221417

Profit & loss

Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.

Consolidated · to 31 Mar 2026
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales1,1962,8612,7552,8452,1782,7523,3163,0703,6883,8904,5654,8595,004
Expenses9672,4862,2282,4481,9822,3382,7793,2013,5443,3623,7633,9334,070
Material Cost1,4761,559
Change in Inventories-18438
Purchases of Stock-in-Trade688362
Employee Cost863929
Other Expenses9201,046
Operating Profit229374527398197414537-131145528803925935
OPM %1913191491516-4.303.9014181919
Other Income87463291643303-43109-11292-1003,313124193
Exceptional items (within Other Income)65-27
Interest4716818319679156150177261280249179172
Depreciation64131126154117174206233243214192202210
Profit before tax99213750969030342289-653-268-653,675669746
Tax %1531121-92711-27-2145214
Net Profit8449544668433031258-474-212-943,598575634
EPS in Rs142124574364.0630-51-22-7.683906067
Diluted EPS in Rs39160
Dividend Payout %7641103834580-7-3318

Compounded growth

Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.

Compounded sales growth

10 years
5%
5 years
8%
3 years
10%
TTM
8%

Compounded profit growth

10 years
16%
5 years
20%
3 years
71%
TTM
55%

Stock price CAGR

10 years
9%
5 years
32%
3 years
67%
1 year
38%

Return on equity

10 years
22%
5 years
31%
3 years
57%
Last year
20%

Balance sheet

What the company owns and what it owes, at the end of each year. ₹ crore.

Consolidated
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital608989909090909090929292
Reserves1,0852,5692,6592,3742,5592,4382,6872,2692,1222,0342,4603,015
Borrowings8923,5423,7002,5203,2212,2352,3483,0253,0302,5171,8801,758
Other Liabilities4381,2111,5981,6011,9371,3691,8441,5561,3521,1571,4981,941
Minority Interest3542
Total Liabilities2,4757,4108,0466,5857,8076,1316,9696,9406,5945,7995,9296,807
Fixed Assets7012,6792,9802,9773,6482,0992,2192,3472,3111,8651,8992,101
CWIP171815780620453413447291151162207447
Investments6301,3411,525588702549697540490303409291
Other Assets9722,5762,7622,4003,0053,0703,6053,7623,6423,4703,4143,967
Total Assets2,4757,4108,0466,5857,8076,1316,9696,9406,5945,7995,9296,807

Cash flows

Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.

Consolidated
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity837328818760205481-25844701684703
Cash from Investing Activity50-2,205-1,222570-1451,321-522-119302-150-90-173
Cash from Financing Activity-4212,944338-1,016194-1,709-16421-214-693-643-453
Net Cash Flow-288812-596-259110-184-5645133-142-4876
Free Cash Flow-157-293-386-212-25658188-326-43672505291

Ratios

How fast customers pay, how long stock sits, and how well capital earns — year by year.

Consolidated
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days1191321321131651241221441291079697
Inventory Days135149209146294254329285257235236305
Days Payable153188221188299259323260220178190244
Cash Conversion Cycle1029212071160119128168165164141157
Working Capital Days-916-122-4-70-70-22-28-11-192438
ROCE %5781116258-5-071518

Shareholding pattern

Who owns the company — founders (promoters), foreign funds, Indian funds and the public. In %.

Consolidated · to 30 Jun 2026
Line itemSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters282726262627282828282828
FIIs171925273028282829302928
DIIs201918181817141313131415
Government0.400.390.390.390.010.010.010.010.010.010.010.01
Public353432292628303031302928
No. of Shareholders1,01,63891,18284,69591,91796,0091,14,23695,12592,88991,20685,58986,61694,850

Price trend

The price as a Renko brick chart: small moves drop out so the bigger path stands out.

Change over 1 year +28.5% (₹852.55 → ₹1,095.30)Brick size ₹42.12 (fixed)Bricks 30
₹800₹1,000₹1,200₹1,095Nov '25Mar '26May '26Jul '26Sep '26
Price moved up one brickPrice moved down one brickLast close ₹1,095.30 on 8 Oct 2026

Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.

Open interestPRO

Where option traders are positioned on this stock.

Industry numbers

The numbers that matter most in this industry, from the company's own filings.

1 when an audit qualification is filed as repetitive

0.00flag

2026-03-31

the company's own unlisted debt securities in default at period end

0.00cr

2026-06-30

the company's own loans / revolving facilities in default at period end (standalone filing)

0.00cr

2026-06-30

net debt from the filed balance sheet at the newest year end: Borrowings − Cash Equivalents − Investments (Current); negative = net cash

1,545inr_cr

2026-03-31

guarantees / comfort given for promoter, promoter group, directors and KMP

0.00cr

2026-03-31

loans outstanding to promoter, promoter group, directors and KMP (governance filing)

0.00cr

2026-03-31

security given for the borrowing of promoter, promoter group, directors and KMP

0.00cr

2026-03-31

FY revenue / permanent employees + workers, same basis (calc)

61,67,284inr

2026-03-31

News

News and filings about Strides Pharma Science Limited. Open one to see why it matters.

No recent news for this company.

Supply chain

Who it buys from, sells to and competes with — as recorded in our map of company links.

Competes with

Uses as raw material

  • Active pharmaceutical ingredients (APIs)
  • Excipients
  • Packing materials

Buys drug ingredients from

Buys from

About

What the company is, from our own records: where it sits, where it makes things, and what it is made of.

Sector
Healthcare
Industry
Pharmaceuticals
Classification
Healthcare › Pharmaceuticals
ISIN
INE939A01011

Plants

  • Beltapharm S.R.L. · Cusano Milanino, Italy
  • Strides Bengaluru Chandapura (SEML) facility
  • Strides Bengaluru KRS Gardens facility
  • Strides Chennai facility
  • Strides Pharma Inc. Chestnut Ridge facility
  • Strides Puducherry facility
  • Universal Corporation Limited (UCL) · Kikuyu Town, Kiambu County, Kenya

News impact

Big market events that reach Strides Pharma Science Limited, and how the effect spreads.

1 Sept, 04:32 IST · Market event · high impact

Trump squeezes mid-size pharma for cheaper US drug prices in a $64 billion savings push, and Sun Pharma agrees to lower its US prices

The White House got nine mid-sized drug companies, including India's Sun Pharma, to agree to charge Americans no more than the lowest price they charge in other rich countries. That caps the most profitable part of Sun Pharma's US business, though past versions of this policy have not actually hurt Indian drugmakers' share prices.

Healthcare

Who it hits first

  • Sun Pharma's US specialty franchise, its highest-margin business, now carries an explicit price ceiling under the agreement it signed.
  • Other US-exposed Indian drugmakers face the headline risk that branded price compression eventually transmits to generic pricing.

Who may gain

  • Generic and active-ingredient suppliers can gain volume if the policy pushes prescriptions toward cheaper medicines - Granules, which sells ingredients and finished doses to US generic makers, rose 11.20% in the week after the May 2025 most-favoured-nation order.
  • Aurobindo Pharma is running a live offsetting positive: its Lannett subsidiary has just launched generic Advair Diskus, a complex inhalation product that carries far better pricing than ordinary generics.
  • Domestically skewed drugmakers such as Alkem are relatively insulated, because a smaller share of their revenue is exposed to US pricing at all.

Along the supply chain

Downstream

US pharmacy benefit managers, insurers and ultimately American patients are the downstream beneficiaries of lower prices. For Indian exporters the practical downstream effect is on contract renewal terms with US distributors and pharmacy chains, which reset annually rather than immediately.

Upstream

Active pharmaceutical ingredient makers sit one layer above the pricing pressure. If US branded prices fall, formulators squeeze their ingredient suppliers on cost, but if the policy also shifts prescription volume toward cheaper generics, the number of doses made goes up - which is what an ingredient supplier gets paid for. Granules sits squarely at this junction, which is why its direction is mixed rather than negative.

Where demand moves

Business

Volume of medicine consumed does not change - people take the same drugs - so this reallocates value along the chain rather than destroying demand. Money moves from branded manufacturers' margins to US payers and patients. Where prescriptions shift from branded to generic alternatives, volume moves toward Indian generic suppliers, which is the mechanism behind the consistently positive historical reaction.

Capital

Within Indian pharma, capital rotates from US-specialty-heavy names such as Sun Pharma toward domestically skewed names such as Alkem and toward complex-generic stories such as Aurobindo Pharma. Because the historical base rate is flat-to-positive, the rotation has been mild rather than a sector-wide de-rating.

How it spreads across sectors

Healthcare

US specialty pricing capped; generic and active-ingredient volumes potentially supported; domestically skewed drugmakers relatively insulated.

When it plays out

Immediate

Sun Pharma opens weaker on the specialty pricing cap; the wider Indian pharma complex is likely to be muted rather than sold off, based on the base rate.

Medium term

The real risk is cumulative: successive orders capping US branded prices, adding pharmaceutical import tariffs and pressuring generic pricing together would eventually compress the US profit pool Indian exporters draw on, even though no single announcement has done so yet.

Short term

Watch which other Indian companies sign most-favoured-nation deals and on what terms. Watch whether the separate generic tariff proposal from July 2026 advances, because that channel HAS produced negative day-one reactions where the pricing orders have not.

Who it hits first

  • Strides Pharma (STAR) deconsolidates subsidiary Pivot Path and receives ~₹100 cr, while retaining a 19.95% associate stake; mildly positive for capital structure and strategic focus

Who may gain

  • No material beneficiary - a small non-core divestiture does not shift market share or demand to pharma peers

Along the supply chain

Downstream

No downstream customer impact - this is an intra-group portfolio/capital action with no change to Strides' formulations supply to customers

Upstream

No supply-chain impact - Pivot Path is a non-core arm being monetised, not a production input; API suppliers LAURUSLABS and SOLARA see no change in Strides offtake

Where demand moves

Business

No business demand shift - the divestiture monetises a non-core subsidiary and does not redirect orders to or from competitors such as MANKIND, CIPLA or DRREDDY

Capital

Mild capital positive for STAR from the cash inflow and cleaner consolidated structure; insufficient size (~1% of market cap) to drive any sector rotation

How it spreads across sectors

Healthcare

Negligible sector ripple - idiosyncratic company-level capital action with no read-through to pharma peers

Dividends, splits & big trades

Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.

Dividends

31 Jul 2026unspecified₹5
22 Jul 2025unspecified₹4
6 Dec 2024demerger₹0
9 Sep 2024unspecified₹2.5
4 Aug 2023unspecified₹1.5
5 Aug 2021unspecified₹2.5
24 Jul 2020unspecified₹2
22 Aug 2019interim₹12

Splits, bonuses & buybacks

  • daily-prices repair: 9 rows from NSE's archive (replace 1, delete 1, insert 7), 2016-10-30..2026-02-01 (docs/flat_day_repair.md)1× · 30 Oct 2016

Bulk & block deals

DateWhoBought / soldSharesPrice
28 Aug 2026SBI LIFE INSURANCE CO.LTD.SELL10,00,000₹990.00
28 Aug 2026ARUN KUMAR PILLAIBUY10,00,000₹990.00

Documents

Annual reports, results presentations and earnings calls, straight from the source.

Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.